ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,877 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBellinzonaHumabs BioMed SA
Humabs BioMed SA Logo
Verified· 3 sources

Humabs BioMed SA

Summary

About the company

The core activity of Humabs BioMed SA is the discovery and development of anti-infective immunotherapies for the treatment of viral and bacterial diseases, including those caused by Zika, Ebola, Rabies, Dengue and other Flaviviruses. The company focuses on the development of therapeutics up to clinical proof of concept and has a broad pipeline of development candidates.

AI-generated
Offering

Products & services

LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Industry:Research & DevelopmentPharmaceutical Industry
✓ Offered7
Development of Immunotherapies
Development of antibody- and T-cell engager–based therapeutics for infectious diseases, cancer and other serious conditions with high unmet medical need.
Antibody and T-cell Engager Development Platform
Platform for the identification, optimisation and further development of antibodies, antibody fragments and T-cell engagers using proprietary discovery methods and AI-supported protein engineering tools.
PRO-XTEN® Masking Platform
Protease-cleavable masking platform for targeted activation of therapeutics in the tumour microenvironment, focusing on T-cell engagers and other applications in oncology and infectious diseases.
Treatment of chronic hepatitis delta
Development of a chronically suppressive therapy with tobevibart and elebsiran; ongoing Phase 3 programme for the treatment of chronic hepatitis delta.
Oncology Therapies
Development of PRO-XTEN®-masked T-cell engagers against HER2, EGFR and PSMA, as well as other undisclosed targets for solid tumours.
Press

Media

September 25, 2017Media
Humabs BioMed acquired by Vir Biotechnology
startupticker.ch

Knowledge

No knowledge articles yet

Once Humabs BioMed SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Humabs BioMed SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Humabs BioMed SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Humabs BioMed SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Via dei Gaggini 3
6500 Bellinzona

At a glance

Legal form
Corporation
UID
CHE-308.820.942
Founded
2024 · 2 years
Last commercial register change
October 6, 2025
Employees
11 to 20

Similar companies

MB
MV BioTherapeutics SA
Bellinzona
AG
Avyxa GmbH
Barbengo
GG
GT Gain Therapeutics SA
Lugano
NP
NOVELTY PHARMA GALENICAL DEVELOPMENT AND DOCUMENTATION SA
Cadempino